mitomycin-c kyowa 10 mg, powder for solution for injection
kyowa kirin holdings b.v. - mitomycin - powder for solution for injection - 10 milligram(s) - other cytotoxic antibiotics; mitomycin
mitomycin-c kyowa 40 mg, powder for intravesical solution
kyowa kirin holdings b.v. - mitomycin - powder for solution for infusion - 40 milligram(s) - other cytotoxic antibiotics; mitomycin
xomolix 2.5 mg/ml solution for injection
kyowa kirin holdings b.v. - droperidol - solution for injection - 2.5 milligram(s)/millilitre - butyrophenone derivatives; droperidol
chlorphenamine 10 mg/ml solution for injection
kyowa kirin holdings b.v. - chlorphenamine maleate - solution for injection - 10 milligram(s)/millilitre - substituted alkylamines; chlorphenamine
pabrinex intravenous high potency concentrate for solution for infusion
kyowa kirin holdings b.v. - ascorbic acid; riboflavine; pyridoxine hydrochloride ; nicotinamide; thiamine hydrochloride; glucose (as monohydrate) - concentrate for solution for infusion - . - vitamin b-complex with vitamin c
rectogesic 4 mg/g rectal ointment
kyowa kirin holdings b.v. - glyceryl trinitrate - rectal ointment - 4 milligram(s)/gram - muscle relaxants; glyceryl trinitrate
xomolix 0.5 mg/ml solution for injection
kyowa kirin holdings b.v. - droperidol - solution for injection - 0.5 milligram(s)/millilitre - butyrophenone derivatives; droperidol
tostran 2% gel
kyowa kirin holdings b.v. - testosterone - gel - 2 percent weight/weight - 3-oxoandrosten (4) derivatives; testosterone
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - drugs for treatment of bone diseases - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
moventig
kyowa kirin holdings b.v. - naloxegol oxalate - constipation; opioid-related disorders - peripheral opioid receptor antagonists, drugs for constipation - treatment of opioid-induced constipation (oic) in adult patients who have had an inadequate response to laxative(s).